A5041059632- Coronary Interventions and Diagnostics
- Cardiac Imaging and Diagnostics
- Antiplatelet Therapy and Cardiovascular Diseases
- Peripheral Artery Disease Management
- Cerebrovascular and Carotid Artery Diseases
- Acute Myocardial Infarction Research
- Cardiac Valve Diseases and Treatments
- Aortic aneurysm repair treatments
- Health Systems, Economic Evaluations, Quality of Life
- Infective Endocarditis Diagnosis and Management
- Sex and Gender in Healthcare
- Cardiovascular Health and Risk Factors
- Cryptography and Residue Arithmetic
- Polynomial and algebraic computation
- Blood Pressure and Hypertension Studies
- Pharmaceutical Economics and Policy
- Cardiac Health and Mental Health
- Vascular Procedures and Complications
- Mobile Health and mHealth Applications
- Electrodeposition and Electroless Coatings
- Safety Warnings and Signage
- Protein Interaction Studies and Fluorescence Analysis
- Infectious Diseases and Tuberculosis
- Diabetic Foot Ulcer Assessment and Management
- Aortic Disease and Treatment Approaches
Boston Scientific (United States)
2014-2024
Phoenix (United States)
2017-2024
Boston Scientific (Netherlands)
2011-2022
Icahn School of Medicine at Mount Sinai
2019
Universidad del Desarrollo
2019
Clínica Alemana
2019
St. Jude Medical Center
2017
Guy's and St Thomas' NHS Foundation Trust
2015
Christ Hospital
2014
Florida State University
2012
Coronary artery bypass grafting (CABG) has been considered the standard of care for patients with three-vessel disease (3VD), but long-term comparative results from randomized trials CABG vs. percutaneous coronary intervention (PCI) using drug-eluting stents (DES) remain limited. Patients de novo 3VD or left main were randomly assigned to PCI paclitaxel-eluting first-generation stent in SYNTAX trial. This pre-specified analysis presents 5-year outcomes (n = 1095). The rate major adverse...
Importance Drug-coated balloons offer a potentially beneficial treatment strategy for the management of coronary in-stent restenosis. However, none have been previously evaluated or approved use in circulation United States. Objective To evaluate whether paclitaxel-coated balloon is superior to an uncoated patients with restenosis undergoing percutaneous intervention. Design, Setting, and Participants AGENT IDE, multicenter randomized clinical trial, enrolled 600 (lesion length...
Background: Prolonged dual antiplatelet therapy (DAPT) after percutaneous coronary intervention is associated with increased bleeding, despite a reduced incidence of ischemic events. The SYNERGY everolimus-eluting stent thin-strut platinum-chromium that elutes everolimus from thin abluminal layer bioabsorbable polymer. These design elements may facilitate rapid endothelialization and enable shorter-duration DAPT. Methods: EVOLVE Short DAPT prospectively evaluated the safety 3-month in high...
Stents were deployed in 83 renal artery lesions of 63 subjects. All hypertensive and 29 insufficient (RI). Technical success was 99%. Long-term (11.3 ± 3.8 months) patency evaluated with ultrasound 69 (51 ostial). long-term rates not significantly different between ostial non-ostial lesions. Ten restenosed (14%). At most recent follow-up (10.2 4.5 subjects classified as cured (3.7%), improved (35.2%), unchanged (53.7%), or worse (7.4%). Systolic pressure throughout but diastolic only lower...
The thin-strut SYNERGY stent has an abluminal everolimus-eluting bioabsorbable polymer coating designed to facilitate vascular healing and reduce risk of thrombosis. In the multicenter, randomized EVOLVE II trial (The Clinical Trial Assess Stent System for Treatment Atherosclerotic Lesion[s]), was noninferior durable PROMUS Element Plus primary end point 1-year target lesion failure. Longer-term clinical follow-up will support relative efficacy safety SYNERGY.Patients with ≤3 native coronary...
<h3>Importance</h3> There exist limited outcomes data for women and minorities after contemporary percutaneous coronary intervention (PCI). <h3>Objective</h3> To examine 1-year in vs white men PCI with everolimus-eluting stents. <h3>Design, Settings, Participants</h3> The PLATINUM Diversity study was a single-arm enrolling minorities. Patient-level pooling the PROMUS Element Plus Post-Approval Study prespecified. Data on social determinants of health language were collected cohort, which...
African American individuals are at a higher risk of premature death from cardiovascular diseases than White individuals, with disproportionate attributable uncontrolled hypertension. Given their high use among mobile technologies, including smartphones, show promise in increasing reliable health information access. Culturally tailored (mHealth) interventions may promote hypertension self-management this population.
Small reference vessel diameter predicts adverse outcomes following coronary stenting. TAXUS Express and Liberté paclitaxel-eluting stents (PES) reduce restenosis compared to bare metal (BMS) in small vessels. Element is a novel thin-strut, platinum chromium stent designed enhance visibility, conformability, drug delivery vessels.The PERSEUS Vessel (SV) prospective, single-arm, superiority trial evaluates the PES 224 subjects with target lesion length≤20 mm diameter≥2.25 <2.75 mm, 125...
To assess the influence of race on long-term outcomes following percutaneous coronary intervention (PCI) with paclitaxel-eluting stents (PES).Data PCI drug-eluting are limited because severe underrepresentation minority populations in randomized trials.We compared 5-year 2,301 whites, 127 blacks, and 169 Asians treated PES TAXUS IV, V, ATLAS trials. Outcomes were adjusted using a propensity score logistic regression model 1:4 matching.Blacks more likely than whites to be female, have history...
Background The impact of race/ethnicity on coronary stent outcomes in women is unknown. We compared baseline characteristics, social determinants health, and 1-year female African Americans (AA) Hispanic/Latinas (HL) versus white after everolimus-eluting implantation all-comer patients. Methods Results pooled 1863 from the PLATINUM Diversity (n=1057 women) PROMUS ELEMENT PLUS (n=806 postapproval studies, with some overlap study sites. Social health data were only available for Diversity....
Drug-coated balloons (DCB) have shown promising results for the treatment of in-stent restenosis (ISR) and small vessel disease (SVD). However, data comparing efficacy different DCBs are limited.
The Agent device consists of a semi-compliant balloon catheter, which is coated with therapeutic low-dose formulation paclitaxel (2 µg/mm
Aims:The PROMUS™ Element™ European Post-Approval Surveillance Study (PE-Prove) is a prospective, open-label, multicentre observational study designed to assess outcomes following PROMUS Element everolimus-eluting stent implantation in an unselected patient population.Methods and results: A total of 1,010 patients were enrolled at 40 clinical sites Europe, including 24.9% with medically treated diabetes, 50.0% Type B2/C lesions, 6.1% chronic occlusion, 17.8% acute myocardial infarction (MI...
Abstract Objective We evaluated 1‐year outcomes after platinum chromium everolimus‐eluting stents (PtCr‐EES) in small versus non‐small coronary arteries within a large, diverse sample of men, women, and minorities. Background There exists limited data on the use second‐generation drug‐eluting stent to treat diameter arteries. Methods pooled patients from PLATINUM Diversity PROMUS Element Plus registries. Small‐vessel percutaneous intervention (SV‐PCI) was defined as ≥1 target lesion with...
Abstract Percutaneous treatment of chronic total coronary occlusions has been limited by procedural complications such as vessel injury or perforation. Optimizing visualization in the with optical coherent reflectometry and a forward‐looking fiberoptic guidance technology may improve safety efficacy percutaneous these lesions. Cathet Cardiovasc Intervent 2001;54:180–187. © 2001 Wiley‐Liss, Inc.
BackgroundHow diabetes mellitus (DM), race/ethnicity, and sex impact ischemic events following coronary artery stent procedures is unknown.MethodsUsing the PLATINUM Diversity PROMUS Element Plus Post-Approval Pooled Study (N = 4184), we examined of sex, DM on outcomes. Primary outcome was 1-year major adverse cardiac (MACE) (MACE composite: death, myocardial infarction [MI], target vessel revascularization).ResultsThe study sample included 1437 diabetic patients (501 White men, 470 women,...